Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | GGH | Q92820 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6948884 | 1.00 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLAPLA2G2CKDM4E | |
| SCHEMBL12626915 | 0.88 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL4363123 | 0.88 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL3773280 | 0.87 | CTSK (0.48) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL863895 | 0.87 | CTSK (0.48) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL863894 | 0.87 | CTSK (0.48) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21685691 | 0.85 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21685690 | 0.85 | FOLH1 (0.42) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL29400405 | 0.85 | FNTA (0.39) | FOLH1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17715147 | 0.85 | L3MBTL1 (0.41) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2019023295-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20180029978-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9802886-B2 | Process for making lysine-glutamic acid dipeptide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170057912-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | FOLH1 163/4885NAALAD2 3775/4885RIMKLA 4773/4885 |
| US-20180029978-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | GLUL, ASNS, QPCT | FOLH1 52/4885NAALAD2 226/4885RIMKLA 39/4885 |
| US-20170057912-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | GLUL, ASNS, QPCT | FOLH1 52/4885NAALAD2 226/4885RIMKLA 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.